210 related articles for article (PubMed ID: 26496700)
1. Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma.
Slemmons KK; Crose LE; Rudzinski E; Bentley RC; Linardic CM
PLoS One; 2015; 10(10):e0140781. PubMed ID: 26496700
[TBL] [Abstract][Full Text] [Related]
2. The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma.
Mohamed A; Sun C; De Mello V; Selfe J; Missiaglia E; Shipley J; Murray GI; Zammit PS; Wackerhage H
J Pathol; 2016 Sep; 240(1):3-14. PubMed ID: 27184927
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
[TBL] [Abstract][Full Text] [Related]
4. A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma.
Slemmons KK; Crose LES; Riedel S; Sushnitha M; Belyea B; Linardic CM
Mol Cancer Res; 2017 Dec; 15(12):1777-1791. PubMed ID: 28923841
[TBL] [Abstract][Full Text] [Related]
5. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
[TBL] [Abstract][Full Text] [Related]
6. Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence.
Li JJ; Kovach AR; DeMonia M; Slemmons KK; Oristian KM; Chen C; Linardic CM
Sci Rep; 2021 Aug; 11(1):16505. PubMed ID: 34389744
[TBL] [Abstract][Full Text] [Related]
7. Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
Schaaf G; Hamdi M; Zwijnenburg D; Lakeman A; Geerts D; Versteeg R; Kool M
Cancer Res; 2010 Jan; 70(2):762-71. PubMed ID: 20068162
[TBL] [Abstract][Full Text] [Related]
8. Potential Value of YAP Staining in Rhabdomyosarcoma.
Ahmed AA; Habeebu SS; Sherman AK; Ye SQ; Wood N; Chastain KM; Tsokos MG
J Histochem Cytochem; 2018 Aug; 66(8):577-584. PubMed ID: 29596030
[TBL] [Abstract][Full Text] [Related]
9. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
[TBL] [Abstract][Full Text] [Related]
10. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Belyea BC; Naini S; Bentley RC; Linardic CM
Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
[TBL] [Abstract][Full Text] [Related]
12. Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma.
Slemmons KK; Yeung C; Baumgart JT; Juarez JOM; McCalla A; Helman LJ
Cancer Res; 2020 Jul; 80(14):3046-3056. PubMed ID: 32354737
[TBL] [Abstract][Full Text] [Related]
13. MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis.
Huang HJ; Liu J; Hua H; Li SE; Zhao J; Yue S; Yu TT; Jin YC; Cheng SY
Oncotarget; 2014 Apr; 5(8):2161-75. PubMed ID: 24811402
[TBL] [Abstract][Full Text] [Related]
14. Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma.
Kovach AR; Oristian KM; Kirsch DG; Bentley RC; Cheng C; Chen X; Chen PH; Chi JA; Linardic CM
Mol Oncol; 2022 Oct; 16(20):3587-3605. PubMed ID: 36037042
[TBL] [Abstract][Full Text] [Related]
15. YAP promotes myogenic differentiation
Chen TH; Chen CY; Wen HC; Chang CC; Wang HD; Chuu CP; Chang CH
FASEB J; 2017 Jul; 31(7):2963-2972. PubMed ID: 28356344
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
[TBL] [Abstract][Full Text] [Related]
17. Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition of the YAP proto-oncogene.
Nguyen HT; Hong X; Tan S; Chen Q; Chan L; Fivaz M; Cohen SM; Voorhoeve PM
Cell Rep; 2014 Aug; 8(3):707-13. PubMed ID: 25088426
[TBL] [Abstract][Full Text] [Related]
18. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.
Yang C; Tan J; Zhu J; Wang S; Wei G
Oncotarget; 2017 Jun; 8(23):37154-37163. PubMed ID: 28415761
[TBL] [Abstract][Full Text] [Related]
19. High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.
Chen R; Zhu S; Fan XG; Wang H; Lotze MT; Zeh HJ; Billiar TR; Kang R; Tang D
Hepatology; 2018 May; 67(5):1823-1841. PubMed ID: 29149457
[TBL] [Abstract][Full Text] [Related]
20. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
